NCT04702841 - CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

December 31, 2022

Conditions

CARMalignant Tumors

Interventions

DRUG

Chimeric antigen receptor modified γδ T cells

Dosage: the total dosage of reinfusion is 0.2-5 × 10\^6 / kg, which is determined according to the body weight of the subject and the effective content of cell preparation.

Trial Locations (1)

230000

RECRUITING

Anhui Provincial Hospital, Hefei